我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
3
0 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
N/A
已完成
100.0%
FDA
Food and Drug Administration
- The FDA has approved a generic estradiol gel, 0.06% (ANI Therapeutics), for treating moderate to severe hot flashes and vaginal changes due to menopause. - The topical gel, a generic version of EstroGel, is administered daily and may require progestin co-administration in women with a uterus to reduce endometrial cancer risk. - Clinical studies showed estradiol gel reduced hot flash frequency by approximately 75% and improved vaginal dryness severity by about 50% in menopausal women. - US annual sales for estradiol gel were approximately $16.7 million, and this generic option aims to provide a more accessible and affordable treatment for patients.
